CGEN COMPUGEN LTD
Nasdaq · SEC CIK 1119774 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $126.3K 11 sales by 2 insiders
- Filings on record
- 23 since 2026-03-30, latest 2026-07-30 16:13
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Levine Zurit | SVP, Business Development | — | $83.4K |
| Ophir Eran | Pres, CEO, Dir | — | $42.9K |
| Kredo Russo Sharon | SVP, Research, Discovery | — | — |
| Mahler Michelle | Chief Medical Off | — | — |
| Perry Eran | Dir | — | — |
| Halevy Gilead | Dir | — | — |
| Livnat Savitzky Kinneret | Dir | — | — |
| Hukkelhoven Mathias | Dir | — | — |
| Silberman David | CFO | — | — |
| ZWEIFACH SANFORD S | Dir | — | — |
Transactions 31
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-07-30 16:13 | 2026-07-29 | CGEN | Levine Zurit | SVP, Business Development | A - Grant | $0.00 | +18.0K | 47.4K | +61% | $0 |
| D | 2026-07-30 16:11 | 2026-07-29 | CGEN | Silberman David | CFO | A - Grant | $0.00 | +19.5K | 55.0K | +55% | $0 |
| D | 2026-07-30 16:08 | 2026-07-29 | CGEN | Perry Eran | Dir | A - Grant | $0.00 | +7,500 | 17.5K | +75% | $0 |
| D | 2026-07-30 16:06 | 2026-07-29 | CGEN | Kredo Russo Sharon | SVP, Research, Discovery | A - Grant | $0.00 | +18.0K | 37.5K | +92% | $0 |
| D | 2026-07-30 16:05 | 2026-07-29 | CGEN | Livnat Savitzky Kinneret | Dir | A - Grant | $0.00 | +7,500 | 20.9K | +56% | $0 |
| D | 2026-07-30 16:04 | 2026-07-29 | CGEN | Hukkelhoven Mathias | Dir | A - Grant | $0.00 | +7,500 | 17.5K | +75% | $0 |
| D | 2026-07-30 16:03 | 2026-07-29 | CGEN | Halevy Gilead | Dir | A - Grant | $0.00 | +7,500 | 18.9K | +66% | $0 |
| D | 2026-07-30 16:02 | 2026-07-29 | CGEN | ZWEIFACH SANFORD S | Dir | A - Grant | $0.00 | +7,500 | 20.2K | +59% | $0 |
| D | 2026-07-30 16:01 | 2026-07-29 | CGEN | Mahler Michelle | Chief Medical Off | A - Grant | $0.00 | +13.5K | 36.6K | +58% | $0 |
| DT | 2026-07-13 16:01 | 2026-07-09 | CGEN | Levine Zurit | SVP, Business Development | M - OptEx | $0.8292 | +1,875 | 31.2K | +6% | +$1,555 |
| DT | 2026-07-13 16:01 | 2026-07-09 | CGEN | Levine Zurit | SVP, Business Development | S - Sale+OE | $2.50 | -1,875 | 29.4K | -6% | -$4,688 |
| DT | 2026-04-27 16:03 | 2026-04-24 | CGEN | Levine Zurit | SVP, Business Development | M - OptEx | $1.15 | +2,000 | 31.4K | +7% | +$2,300 |
| DT | 2026-04-27 16:03 | 2026-04-24 | CGEN | Levine Zurit | SVP, Business Development | S - Sale+OE | $3.20 | -2,000 | 29.4K | -6% | -$6,400 |
| DT | 2026-04-27 16:02 | 2026-04-24 | CGEN | Ophir Eran | Pres, CEO, Dir | M - OptEx | $0.8292 | +5,000 | 16.4K | +44% | +$4,146 |
| DT | 2026-04-27 16:02 | 2026-04-24 | CGEN | Ophir Eran | Pres, CEO, Dir | S - Sale+OE | $3.20 | -5,000 | 11.4K | -31% | -$16.0K |
| DT | 2026-04-15 16:10 | 2026-04-14 | CGEN | Ophir Eran | Pres, CEO, Dir | M - OptEx | $0.8292 | +5,000 | 16.4K | +44% | +$4,146 |
| DT | 2026-04-15 16:10 | 2026-04-14 | CGEN | Ophir Eran | Pres, CEO, Dir | S - Sale+OE | $2.90 | -5,000 | 11.4K | -31% | -$14.5K |
| DT | 2026-04-15 16:07 | 2026-04-14 | CGEN | Levine Zurit | SVP, Business Development | M - OptEx | $1.15 | +2,000 | 31.4K | +7% | +$2,300 |
| DT | 2026-04-15 16:07 | 2026-04-14 | CGEN | Levine Zurit | SVP, Business Development | S - Sale+OE | $2.80 | -2,000 | 29.4K | -6% | -$5,600 |
| DMAT | 2026-04-15 16:03 | 2026-04-10 | CGEN | Levine Zurit | SVP, Business Development | M - OptEx | $1.03 | +3,125 | 32.5K | +11% | +$3,233 |
| DAT | 2026-04-15 16:03 | 2026-04-10 | CGEN | Levine Zurit | SVP, Business Development | S - Sale+OE | $2.56 | -3,125 | 29.4K | -10% | -$8,012 |
| DMT | 2026-04-13 16:04 | 2026-04-10 | CGEN | Levine Zurit | SVP, Business Development | M - OptEx | $1.03 | +3,125 | 32.5K | +11% | +$3,233 |
| DT | 2026-04-13 16:04 | 2026-04-10 | CGEN | Levine Zurit | SVP, Business Development | S - Sale+OE | $2.56 | -3,125 | 29.4K | -10% | -$8,012 |
| DMT | 2026-04-09 16:05 | 2026-04-07+ | CGEN | Levine Zurit | SVP, Business Development | M - OptEx | $0.8699 | +7,875 | 34.8K | +29% | +$6,851 |
| DMT | 2026-04-09 16:05 | 2026-04-07+ | CGEN | Levine Zurit | SVP, Business Development | S - Sale+OE | $2.38 | -7,875 | 29.4K | -21% | -$18.8K |
| DMT | 2026-04-03 07:31 | 2026-04-01 | CGEN | Levine Zurit | SVP, Business Development | M - OptEx | $0.9209 | +3,500 | 32.9K | +12% | +$3,223 |
| DT | 2026-04-03 07:31 | 2026-04-01 | CGEN | Levine Zurit | SVP, Business Development | S - Sale+OE | $2.20 | -3,500 | 29.4K | -11% | -$7,700 |
| DT | 2026-04-03 07:29 | 2026-04-01 | CGEN | Ophir Eran | Pres, CEO, Dir | M - OptEx | $0.8292 | +5,625 | 17.0K | +49% | +$4,664 |
| DT | 2026-04-03 07:29 | 2026-04-01 | CGEN | Ophir Eran | Pres, CEO, Dir | S - Sale+OE | $2.21 | -5,625 | 11.4K | -33% | -$12.4K |
| D | 2026-03-30 | 2026-03-26 | CGEN | Levine Zurit | SVP, Business Development | M - OptEx | $0.83 | +11.9K | 41.2K | +40% | +$9,856 |
| D | 2026-03-30 | 2026-03-26 | CGEN | Levine Zurit | SVP, Business Development | S - Sale+OE | $2.04 | -11.9K | 29.4K | -29% | -$24.2K |
Purchase Sale Sale after option exercise All abbreviations